← Back to Search

Antibiotic

Doxycycline for Cardiac Amyloidosis

Phase 2 & 3
Waitlist Available
Research Sponsored by IRCCS Policlinico S. Matteo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18.
Newly-diagnosed AL amyloidosis.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is testing whether doxycycline, a commonly used antibiotic, can improve survival in patients with a rare disease where abnormal proteins deposit in bodily organs and severely impair their function.

Eligible Conditions
  • Cardiac Amyloidosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
proportion surviving

Side effects data

From 2021 Phase 4 trial • 26 Patients • NCT04167085
4%
Sinus infection
4%
Foot infection
4%
Metastatic lung cancer dx
4%
Blurred vision
4%
Emesis
4%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Doxycycline
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental interventionExperimental Treatment1 Intervention
doxycycline (100 mg bid)
Group II: Control interventionActive Control1 Intervention
Standard of care therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Doxycycline
2008
Completed Phase 4
~2430

Find a Location

Who is running the clinical trial?

IRCCS Policlinico S. MatteoLead Sponsor
119 Previous Clinical Trials
105,289 Total Patients Enrolled

Frequently Asked Questions

~3 spots leftby Mar 2025